Cue Biopharma Q2 2026: $153M Net Loss, $17.4M Cash, CUE-221 IND Submitted
CUE has more than doubled off its 52-week low of $4.971.
Summary
A $153.1M Q2 net loss, driven by one-time charges from the CUE-221 license deal, left Cue Biopharma with $17.4M in cash. The company has submitted an IND for CUE-221 in food allergy and expects Phase 2 data by the end of Q3 2026.
Key Events · Earnings and Guidance · CUE
-
Q2 Net Loss of $153.1M
The net loss for Q2 2026 reached $153.1 million, a sharp increase from $8.5 million in Q2 2025, driven by one-time non-cash losses and expenses related to the CUE-221 license agreement with Ascendant.
-
Cash Position Drops to $17.4M
Cash and cash equivalents stood at $17.4 million as of June 30, 2026, down from $27.1 million at year-end 2025, following one-time cash outflows related to the license agreement. A $50 million private placement completed after quarter-end provides additional runway.
-
CUE-221 IND Submitted to FDA
An Investigational New Drug (IND) application for CUE-221 in food allergy applications was recently submitted to the FDA, with Phase 2 data in Chronic Spontaneous Urticaria anticipated by the end of Q3 2026.
-
CUE-401 Phase 1 Initiation Planned
Cue Biopharma anticipates submitting an IND for CUE-401 and initiating a Phase 1 clinical study by year-end 2026.
Analysis · CUE · Life Sciences
The second quarter of 2026 brought a staggering net loss of $153.1 million for Cue Biopharma, driven by one-time non-cash charges and payments tied to the CUE-221 license agreement with Ascendant. Cash reserves have dwindled to $17.4 million as of June 30, 2026, though a subsequent $50 million private placement offers some runway. Near-term milestones that could significantly move the stock include the IND submission for CUE-221 in food allergy and the anticipated Phase 2 data readout by the end of Q3 2026.
At the time of this filing, CUE was trading at $34.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.7M. The 52-week trading range was $4.97 to $45.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.